Timestamp

Describe any USPTO data (or information about USPTO processes) that are not currently available publicly, and that would foster useful research if they were systematically assembled and released.

What characteristics of this data or information are important for the uses you have in mind?

Describe the research that would be facilitated by the availability of these new data or information. How would it improve on research that is possible today?

Outside of releasing new data, are there USPTO policies or practices that you would like to see changed to facilitate research on the patent system?

Timeline of trademark registrations, clustered by related marks, showing when each comes into and falls out of force

Explicit rather than implicit end dates; explicit clustering of related marks; some cluster ID

Understanding the evolution of a coherent family of marks over time, seeing gaps in registration coverage; distinguishing when similar marks in different fields appear vs. when a founding company branches out into a new field under the old mark.

A feed of new data products of all kinds, w/ links to existing products that it enhances or supercedes

clean & processed identifiers of patented or patent-related drug compounds

understanding IP-related issues in the pharmaceutical sector

firms' strategic patenting behavior; drug prices and patents; currently most health economists don't use patent data given the lack of relevant training and easily accessible compound-specific patent data.

hold more educational workshops (online) for interested learners

xw377@cornell.edu

-Better mapping from patent assignees to standardized company name, company type and location (i.e., public: ticker, private company: address, incorporated/registered year; individual).

-Assignee and acquisition history (e.g. Wyeth Pharma patent granted in 2008....would be nice to see have file indicating whether or not the patent became owned by Pfizer in the 2009 merger)

-Outcomes of patent litigation (to go with the Patent litigation dockets file:https://www.uspto.gov/ip-policy/economic-research/research-datasets/patent-litigation-docket-reports-data)

-pairwise patent text similarity files (or at least max backwards similarity, overall and within CPC)

jkrieger@hbs.edu

Pre-Nov 2000 data on applications to the USPTO that were not granted patents

The post-Nov 2000 "unsuccessful patent applications" data has been incredibly useful in facilitating a variety of research projects

I understand that these data can't be made publicly available, but it would be great to set up -- if possible -- a standardized, streamlined process through which students or others could visit the USPTO to analyze this data for research purposes.

hlwill@stanford.edu

assignees' or innovators' characteristics, where else (eg. EPO, etc.) being IP protected.

The merge of individual and firm (not just public firms but also private ones) characteristics and other syndicated databases

These characteristics could help analyze incentives and responses to innovate in different environment

Availability of panel data or merged data, if available

Better mapping from patent assignee to company name or ticker, as well as better tracking of the assignment changes between companies.

To understand the intellectual property development in the pharmaceutical industry.

why do firms strategically choose research/patent areas, firm behaviors. Currently, there is still a gap in research on firm's motivation, efficiency and behaviors.

A list of the different data source where students can go and merge data if the data cannot be released publicly.

xixi.hu@sauder.ubc.ca

Standardized data on ultimate owner (or what attorneys call “Real Party in Interest”).

Creating improvements to the dynamic assignee panel

Better measurement for papers with assignee effects, and improved patent-to-firm matching

Ideally, PTO should adopt rules requiring assignees to reveal RPI (for public benefit).

Curated data on ex post outcomes in PTAB and courts. There is lots to unpack here, but the general idea is to track: Was it ever asserted? Was it ever challenged at PTAB? Did a court ever rule on validity or infringement? Did the owner ever make a public licensing commitment? See, generally: https://patentlyo.com/patent/2021/06/contreras-shepardizing-patents.html

Systematic collection of ex post "quality" metrics

Would enable more research into relationship between prosecution and long-term inidicia of "quality" as interpreted by PTAB and district courts